Naples

• A study to determine the effectiveness, safety, and tolerability of the Recombinant Von Willebrand Factor administered with or without Advat … Ended
  2023-509769-18-00 5 2017-03-15 Hereditary severe von Willebrand Disease in children
• A Phase III, Randomized, Double-blind Study to Evaluate Pembrolizumab plus Chemotherapy vs Placebo plus Chemotherapy as Neoadjuvant Therapy … Ended
  2022-501382-49-00 5 2017-03-07 Triple Negative Breast Cancer (TNBC)
• Ramucirumab plus Irinotecan / Leucovorin / 5-FU versus Ramucirumab plus Paclitaxel in patients with advanced or metastatic adenocarcinoma of … Ended
  2024-512934-14-00 5 2016-11-07 advanced or metastatic adenocarcinoma of the stomach or gastroesophage
• A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of Niraparib Maintenance Treatment in Patients with Advanced Ovar … Ended
  2023-508010-42-00 5 2016-09-14 Homologous recombination deficiency advanced ovarian cancer
• autologous Transplantation after a Rituximab/Ibrutinib/Ara-c containing iNduction in Generalized mantle cell Lymphoma – a randomized Europea … Ended
  2024-511235-10-00 5 2016-07-25 Generalized mantle cell Lymphoma
• A Phase III, Randomized, Open-label, Clinical Trial to Compare Pembrolizumab with Brentuximab Vedotin in Subjects with Relapsed or Refractor … Ended
  2022-500400-22-00 5 2016-06-23 Hodgkin lymphoma
• Adjuvant Treatment for High-risk Triple Negative Breast Cancer Patients With the Anti-PD-l1 Antibody Avelumab (A-Brave) Ended
  2024-514515-10-00 5 2016-06-16 Breast Cancer
• Safety Study of Anti-LAG-3 With and Without Anti-PD-1 in the Treatment of Solid Tumors Ended
  2023-508067-70-00 9 2015-04-15 Neoplasms by site
• A Phase III Prospective Double Blind Placebo Controlled Randomized Study of Adjuvant MEDI4736 in Completely Resected Non-Small Cell Lung Can … Ended
  2024-517856-36-00 5 2015-03-09 Completely resected primary stage IB (≥ 4cm), II and IIIA non-small ce
• Multicenter trial with carfilzomib combined with lenalidomide or cyclophopshamide with or without autologous transplant in newly diagnosed m … Ended
  2024-516630-35-01 4 2015-01-12 NEWLY DIAGNOSED MULTIPLE MYELOMA (MM) PATIENTS ELEGIBLE FOR AUTOLOGOUS
• A Phase 3 Study of Nivolumab plus Ipilimumab Versus Sunitinib in untreated Subjects with Advanced or Metastatic Renal Cell Carcinoma (RCC) Ended
  2023-504761-23-00 5 2014-11-19 Advanced or metastatic renal cell carcinoma
• ROMIDEPSIN IN COMBINATION WITH CHOEP AS FIRST LINE TREATMENT BEFORE HEMATOPOIETIC STEM CELL TRANSPLANTATION IN YOUNG PATIENTS WITH NODAL PER … Ended
  2024-511639-83-00 9 2014-09-01 Anaplastic Large T-cell Lymphoma ALK negative
• Phase 3 Frontline Therapy Trial in Patients With Advanced Classical Hodgkin Lymphoma Ended
  2023-506419-16-00 5 2013-01-08 Advanced Classical Hodgkin Lymphoma
• A Phase 1/2 Study of DCC-3116 in Patients With MAPK Pathway Mutant Solid Tumors Ended
  2022-501474-19-00 7 Non-Small Cell Lung Cancer
• Brightline-4: A study to test how well brigimadlin is tolerated by people with a type of cancer called dedifferentiated liposarcoma Ended
  2023-504522-19-00 5 dedifferentiated liposarcoma
• A dose-finding study to evaluate mRNA-3210 in participants with phenylketonuria Ended
  2023-506963-32-00 7 Participants with Phenylketonuria
• MK-1200 for Advanced Solid Tumors Ended
  2023-508684-68-00 9 Advanced solid tumor
• Phase 3 Study of Tamibarotene Plus Azacitidine in Patients Selected for RARA-positive Higher-risk MDS (SELECT-MDS-1) Ended
  2023-510361-97-00 5 Newly Diagnosed RARA-positive Adult Patients with Higher-risk Myelodys
• An Open-Label, Multicenter, Phase 1 Study Evaluating the Safety and Pharmacokinetics of ADU-1604 in Adults with Advanced Melanoma Ended
  2024-511949-19-00 1 Metastatic Melanoma
• A study to investigate the efficacy and safety of luveltamab tazevibulin versus IC chemotherapy in women with ovarian cancer (including fall … Ended
  2024-512477-27-00 4 Advanced Epithelial Ovarian Cancer (including Fallopian Tube or Primar
• Pharmacodynamics and safety of human recombinant luteinising hormone in hypogonadotropic hypogonadal men Ended
  2024-518159-52-02 10 Hypogonadotropic hypogonadism
• A study to investigate the safety, tolerability, pharmacokinetics (PK), and preliminary anticancer activity of GSK4524101 alone or with nira … Ended
  2024-520197-36-00 7 Neoplasms
• Electrochemotherapy as a first line treatment in recurrent squamous cell carcinoma of the oral cavity and oropharynx: a randomized controlle … Ended
  2025-520735-16-00 4 CARCINOMA OF THE ORAL CAVITY AND OROPHARYNX
• A Phase 1/1b Open-Label Dose-Escalation and Dose-Optimization Study of Bcl-2 Inhibitor BGB 21447 in Patients With Mature B Cell Malignancies Ended
  2025-521600-21-00 1 mature B-Cell malignancies

Showing 1,153–1,176 of 1,177 trials